Royalty Pharma has acquired an interest in Ionis Pharmaceuticals Inc.’s royalty in Biogen’s Spinraza (nusinersen) and Novartis’ pelacarsen for up to $1.125 billion, including an upfront payment of $500 million and up to $625 million in additional pelacarsen milestone payments.   Spinraza is the global foundation of care for the treatment of people living with spinal muscular atrophy (SMA). Biogen licensed Spinraza from Ionis in 2016. Pelacarsen is a treatment specifically tar...